AdenocarcinomaAntineoplastic Agents, ImmunologicalCirculating Tumor DNA
Dr. Michael John Jelinek, MD
NPI1720426513PAC ID3375776297
- Medicare services, 2024
- 1,228
- Medicare patients, 2024
- 243
- Part D claims, 2024
- 681
- Publications
- 21
- Clinical trials
- 2
- Practice address
- 1653 West Congress Parkway, Chicago, IL 60612
- Practice phone
- Call (312) 942-5000
- Professional email
- Get professional email
- Personal email
- Get personal email
- Mobile number
- Get mobile number
Primary practice
Find Dr. Jelinek's professional email, personal email and mobile number
Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.
Dr. Michael John Jelinek is a medical oncologist in Chicago, Illinois
Dr. Jelinek practices at Rush University Medical Center in Chicago, Illinois, part of Rush System for Health.
Dr. Jelinek's NPI, 1720426513, was assigned on June 13, 2013. Dr. Jelinek graduated from Rush Medical College in 2013. Dr. Jelinek holds Illinois license 036-139717.
NPI and contact details
- NPI
- 1720426513NPI Registry (opens in a new tab)
- Medicare PAC ID
- 3375776297
- NPI enumeration date
- June 13, 2013
- NPI status
- Active
- Accepts Medicare assignment
- Yes
- Offers telehealth
- Yes
- Practice phone
- (312) 942-5000
- Professional email
- Get email
- Personal email
- Get email
- Mobile number
- Get number
- Sex
- Male
- Estimated age
- 39
- Medical school graduation
- 2013
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; Dmand AI Affiliation Data; and Doctors and Clinicians National Downloadable File (CMS)
Dr. Michael John Jelinek practices at Rush University Medical Center in Chicago, Illinois
Dr. Jelinek's primary practice is Rush University Medical Center, at 1653 West Congress Parkway, Chicago, IL 60612 in Cook County. The practice phone is (312) 942-5000.
- Rush University Medical Center1653 West Congress Parkway, Chicago, IL 60612 · Cook CountyPhone(312) 942-5000
Source: Dmand AI Affiliation Data
Dr. Michael John Jelinek is affiliated with 4 sites of care and 1 medical group
Dr. Jelinek's primary practice is Rush University Medical Center in Chicago, Illinois, part of Rush System for Health. Dr. Jelinek is also affiliated with Rush Oak Park Hospital. The medical group on file is Rush University Internists. Dmand AI also links Dr. Jelinek to 1 more hospital and 1 group practice or clinic, each named with a free account.
Rush Oak Park HospitalRush University Internists1 hospitalName with a free account1 group practice or clinicName with a free account
See all 5 affiliations for Dr. JelinekSources: Dmand AI Affiliation Data; and Dmand AI Org Hierarchy Data
Dmand AI tracks the EHR system at Dr. Michael John Jelinek's practice
Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Jelinek practices, 4 sites in all. Vendor and product names are available with a free account.
| Site | EHR vendor and product |
|---|---|
| Rush University Medical Center | Available with a free account |
| +3 more affiliated sites | Available with a free account |
Source: Dmand AI Technology Install Data
For health IT teams
See the EHR and IT leaders at every hospital where Dr. Jelinek practices
Dmand AI maps EHR vendors, IT decision makers and buying committees across Rush System for Health and 6.2K+ hospitals, with verified contacts in the same login.
Dr. Michael John Jelinek is one of 153 medical oncologists in Illinois
Medical oncology is Dr. Jelinek's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Jelinek is board certified in internal medicine by the American Board of Internal Medicine. Dr. Jelinek is licensed in Illinois.
Specialties and state licenses
- Medical oncology, IllinoisPrimary
Clinical focus
Dmand AI lists chronic leukemia, lung cancer and prostate cancer among the conditions Dr. Jelinek treats.
Medical oncologists near Dr. Jelinek
Counts of medical oncologists with a Dmand AI profile, by place and practice. Each opens the list.
153medical oncologists in Illinois67medical oncologists in Chicago10medical oncologists at Rush University Medical Center
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks
Dr. Michael John Jelinek billed Medicare for 1,228 services in 2024
CMS data shows 1,228 Medicare services from Dr. Jelinek across 6 procedure codes in 2024, for 243 Medicare patients. Medicare paid $84,614 for them.
Medicare services, 20241,228
Medicare patients243
Paid by Medicare$84,614
Procedure codes6
Dr. Jelinek's Medicare services by type, 2023 to 2024
- 2023
- 2024
- Office and hospital visits
- 2023: 7422024: 7653%
- Other services
- 2023: 02024: 463
Where Dr. Jelinek's Medicare services took place, 2024
- In an office37030%
- In a facility85870%
Dr. Jelinek compared with the Illinois median for medical oncologists, 2024
- Dr. Jelinek
- Illinois median
- Medicare services
- 1,228vs 67183% above
- Medicare patients
- 243vs 2306% above
- Part D claims
- 510vs 34548% above
Medians across 140 medical oncologists in Illinois with Dmand AI profiles that report each measure.
Dr. Jelinek's most billed Medicare procedure codes, 2024
CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.
Need commercial claims for Dr. Jelinek?
Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Jelinek and other medical oncologists in Illinois.
Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks
Dr. Michael John Jelinek treated 243 Medicare patients in 2024, average age 75
CMS counts 243 Medicare patients who saw Dr. Jelinek in 2024. The largest group is 65 to 74, with 123 patients. 74% of them have high blood pressure, and 74% have high cholesterol. 17% are also on Medicaid. Their average risk score is 2.24, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.
Across all payers, Dmand AI patient panel data puts Dr. Jelinek's median patient age at 71, with 35% women.
Medicare patients, 2024243
Average age75
Average risk score2.24
Also on Medicaid17%
Dr. Jelinek's Medicare patients by age, 2024
CMS leaves out age groups with fewer than 11 patients.
Dr. Jelinek's Medicare patients by sex, 2024
- Women8736%
- Men15664%
Chronic conditions among Dr. Jelinek's Medicare patients, 2024
- High blood pressure74%
- High cholesterol74%
- Ischemic heart disease50%
- Arthritis41%
- Diabetes31%
- Cancer30%
- COPD26%
- Chronic kidney disease26%
Share of Medicare patients with each condition. A patient can have several.
Dr. Jelinek's patients across all payers
Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.
Patient panel by age, all payers
Median age 71
Patient panel by sex, all payers
- Women35%
- Men65%
Sources: Dmand AI Patient Panel Data; and Medicare Physician & Other Practitioners - by Provider (CMS), 2024 data
Dr. Michael John Jelinek wrote 681 Medicare Part D claims in 2024
In 2024, Dr. Jelinek wrote 681 Medicare Part D claims for 121 patients. 81% of them were for generic drugs. CMS names the drug for 510 of them, across 18 drugs with 11 or more claims each, at $674,099 in total drug cost. In 2023, CMS named 489 claims across 16 drugs.
Part D claims, 2024681
Drugs named by CMS18
Total drug cost$674,099
Part D patients121
Dr. Jelinek's Part D claims by kind of drug, 2024
- Generic549 claims81%
- Brand-name132 claims19%
Dr. Jelinek's most prescribed drugs by claims, 2024
CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.
Drug classes CMS tracks in Dr. Jelinek's Part D claims, 2024
- Opioids17%116 of 681 claims
- Antibiotics2%15 of 681 claims
Share of all Part D claims for each drug class CMS reports on. Classes with no claims are left out.
Part D claims for drugs CMS names, 2023 to 2024
- 2023
- 2024
- Claims for drugs CMS names
- 2023: 4892024: 5104%
Drugs named by CMS: 18 in 2024, 16 in 2023.
Sources: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026; and Medicare Part D Prescribers - by Provider (CMS), 2024 data
Dr. Michael John Jelinek offers telehealth to Medicare patients
Dr. Jelinek accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Jelinek as offering telehealth.
- Accepts Medicare assignment
- Yes
- Offers telehealth
- Yes
Source: Doctors and Clinicians National Downloadable File (CMS)
For MedTech and pharma teams
Find medical oncologists like Dr. Jelinek by procedure volume and prescribing
Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.
Dr. Michael John Jelinek has 21 publications on record
Dmand AI links 21 papers to Dr. Jelinek, published from 2017 to 2025. 2023 was the busiest year, with 3. The most frequent topics are Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck and Antineoplastic Combined Chemotherapy Protocols. Dr. Jelinek has published most often in Oral Oncol. Dr. Jelinek's most frequent co-authors are Samer Al-Khudari, MD, Nikhil Shashikant Joshi, MD and Nikhil Joshi, MD.
Papers21
Years published2017 to 2025
Dr. Jelinek's papers by year, 2017 to 2025
Topics Dr. Jelinek writes about most
- Head and Neck Neoplasms
- Squamous Cell Carcinoma of Head and Neck
- Antineoplastic Combined Chemotherapy Protocols
- ErbB Receptors
- Lung Neoplasms
- Nivolumab
- Protein Kinase Inhibitors
- Acrylamides
Dr. Jelinek's most frequent co-authors
- Samer Al-Khudari, MD5 shared papers
- Nikhil Shashikant Joshi, MD5 shared papers
- Nikhil Joshi, MD5 shared papers
Recent publications by Dr. Jelinek
Air PollutantsAir PollutionEnvironmental Exposure
Pract Radiat Oncol
Head and Neck NeoplasmsImmobilizationNeck
Head Neck
ChemoradiotherapyHead and Neck NeoplasmsLaryngeal Neoplasms
See who Dr. Jelinek researches with
Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Jelinek works with, so you can find a warm path to the right medical oncologists.
Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage
Dr. Michael John Jelinek has worked on 2 clinical trials
Dmand AI links Dr. Jelinek to 2 clinical trials. 2 are still active or recruiting. Conditions studied include Oropharyngeal Neoplasms and Pharyngeal Neoplasms.
Clinical trials with Dr. Jelinek by phase
- NonePhase 1: no trials
- 1Phase 1/2: 1 trial
- NonePhase 2: no trials
- 1Phase 2/3: 1 trial
- NonePhase 3: no trials
- NonePhase 4: no trials
Conditions in Dr. Jelinek's trials
- Oropharyngeal Neoplasms
- Pharyngeal Neoplasms
Investigators on the most trials with Dr. Jelinek
- Erin R. Alesi, MD1 shared trial
- Krishna C. Alluri, MD1 shared trial
- Youssef M. Arshoun, MD1 shared trial
Recent clinical trials with Dr. Jelinek
A Study of EP0031 in Patients With Advanced RET-altered Malignancies (opens in a new tab)
RecruitingPhase 1/2
EP0031
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer (opens in a new tab)
Active, not recruitingPhase 2/3
Oropharyngeal NeoplasmsPharyngeal NeoplasmsCisplatinNivolumabImage Guided Radiation Therapy
Sources: Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)
Dr. Michael John Jelinek received $180 in industry payments from 2017 to 2022
CMS Open Payments shows 2 general payments to Dr. Jelinek from 2 drug and device companies from 2017 to 2022. Food and beverage make up the largest share, 100% of the total. Millennium Pharmaceuticals, Inc. paid the most, $141.
General payments to Dr. Jelinek by program year, 2017 to 2022
Companies that paid Dr. Jelinek the most, 2017 to 2022
Share is of all general payments to this clinician.
Source: Open Payments (CMS), 2025 data, released July 7, 2026
Dr. Michael John Jelinek graduated from Rush Medical College
Dr. Jelinek graduated from Rush Medical College in 2013.
- Medical school
- Board certified in internal medicine
- Board certified in medical oncology
Source: Dmand AI Professional Profile Data
Dr. Michael John Jelinek accepts plans from 17 insurance carriers
Dr. Jelinek is in network with 17 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.
- Aetna
- Elevance
- Blue Cross Blue Shield of Michigan
- Cigna
- HCSC
- United Healthcare
- Humana
- Aspirus Health Plan
- +9 more carriersWith a free account
Plan types Dr. Jelinek accepts, by number of carriers
- PPO12
- Medicare10
- HMO9
- POS7
- EPO4
Source: Dmand AI Insurance Network Data
Sources for Dr. Michael John Jelinek's profile data
| Data on this page | Source |
|---|---|
| NPI, name, sex, specialty and licenses | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data |
| Practice locations and phone | Dmand AI Affiliation Data |
| Primary practice, affiliations and health system | Dmand AI Affiliation DataDmand AI Org Hierarchy Data |
| Medicare services and procedure codes | Medicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab) |
| State medians for the same specialty | Dmand AI Peer Benchmarks |
| Medicare patients and the all-payer patient panel | Dmand AI Patient Panel DataMedicare Physician & Other Practitioners - by Provider (CMS) (opens in a new tab) |
| Part D prescribing | Medicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab)Medicare Part D Prescribers - by Provider (CMS) (opens in a new tab) |
| MIPS scores, telehealth, assignment and procedure percentiles | Doctors and Clinicians National Downloadable File (CMS) (opens in a new tab) |
| Publications, topics and co-authors | PubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage |
| Clinical trials and co-investigators | Dmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab) |
| Industry payments | Open Payments (CMS) (opens in a new tab) |
| Training, board certification and memberships | Dmand AI Professional Profile Data |
| Insurance carriers and plan types | Dmand AI Insurance Network Data |
| EHR at each practice site | Dmand AI Technology Install Data |
| Similar physicians | Dmand AI Affiliation Data |
Data last refreshed October 2026Report an inaccuracyRemove my information
FAQ
Frequently asked questions about Dr. Michael John Jelinek
Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.
What is Dr. Michael John Jelinek's NPI number?
Dr. Michael John Jelinek's NPI number is 1720426513. It was assigned on June 13, 2013, and it is active in the NPI Registry.
What kind of doctor is Dr. Michael John Jelinek?
Dr. Michael John Jelinek is a medical oncologist in Chicago, Illinois. The primary specialty in the NPI Registry is Medical Oncology Physician (taxonomy code 207RX0202X).
Where does Dr. Michael John Jelinek practice?
Dr. Jelinek practices at 1653 West Congress Parkway, Chicago, IL 60612. Dr. Jelinek's primary practice is Rush University Medical Center in Chicago, Illinois, part of Rush System for Health. Dmand AI also links Dr. Jelinek to 1 hospital and 1 group practice or clinic.
What is Dr. Michael John Jelinek's office phone number?
The practice phone on file for Dr. Jelinek is (312) 942-5000.
What is Dr. Michael John Jelinek's medical license number?
Dr. Jelinek holds Illinois license 036-139717.
Which hospitals is Dr. Michael John Jelinek affiliated with?
Dr. Jelinek practices at Rush University Medical Center in Chicago, Illinois. Dr. Jelinek is also affiliated with Rush Oak Park Hospital. Dmand AI links Dr. Jelinek to 1 more hospital.
What medical group is Dr. Michael John Jelinek part of?
Dr. Jelinek is linked to Rush University Internists.
Does Dr. Michael John Jelinek accept Medicare?
Yes. CMS data shows Dr. Jelinek billed Medicare for 1,228 services in 2024, and Dr. Jelinek accepts Medicare assignment.
Does Dr. Michael John Jelinek offer telehealth?
Yes. The CMS Doctors and Clinicians file lists Dr. Jelinek as offering telehealth services.
How many Medicare patients does Dr. Michael John Jelinek see?
CMS counts 243 Medicare patients who saw Dr. Jelinek in 2024, with an average age of 75.
Show 9 more questionsShow fewer questions
Is Dr. Michael John Jelinek board certified?
Yes. Dr. Jelinek is board certified in internal medicine by the American Board of Internal Medicine.
What services does Dr. Michael John Jelinek bill to Medicare?
In 2024, Dr. Jelinek's most billed Medicare services were medicare service (G2211), office visit, established patient (99215) and office visit, established patient (99214).
Where did Dr. Michael John Jelinek go to medical school?
Dr. Jelinek graduated from Rush Medical College in 2013.
What drugs does Dr. Michael John Jelinek prescribe most?
In 2024 Medicare Part D data, Dr. Jelinek's most prescribed drugs by claims were Ondansetron HCl, Levothyroxine Sodium and Prednisone.
Has Dr. Michael John Jelinek received payments from drug or device companies?
CMS Open Payments shows $180 in general payments to Dr. Jelinek from 2 companies from 2017 to 2022. The largest total came from Millennium Pharmaceuticals, Inc.
How long has Dr. Michael John Jelinek been practicing?
Dr. Jelinek graduated from medical school in 2013, 13 years ago.
Does Dr. Michael John Jelinek do research?
Dmand AI links 21 publications to Dr. Jelinek, published from 2017 to 2025. Dr. Jelinek has worked on 2 clinical trials.
Who does Dr. Michael John Jelinek publish with?
Dr. Jelinek's most frequent co-authors are Samer Al-Khudari, MD (5 shared papers), Nikhil Shashikant Joshi, MD (5 shared papers) and Nikhil Joshi, MD (5 shared papers).
What insurance does Dr. Michael John Jelinek accept?
Dr. Jelinek is in network with 17 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.
Selling to medical oncology practices?
See medical oncologists in Illinois by site of care and group
Find the practices, groups and hospitals they work with, and the right people to contact at each.
- 30 days free
- Self-serve
- No credit card